ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications
ProBioGen AG and TissUse GmbH have signed a license and cooperation agreement to integrate ProBioGen’s Human Artificial…
ProBioGen AG and TissUse GmbH have signed a license and cooperation agreement to integrate ProBioGen’s Human Artificial…
ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding te…
ProBioGen AG and Bio Farma signed an agreement for the development of a biosimilar Trastuzumab for cancer treatment. The…
ProBioGen AG and Tizona Therapeutics, Inc. have signed a commercial license and service agreement for cell line and proc…
. GlymaxX® GlymaxX® is a technology to permanently modify animal cells to produce afucosylated antibodies/proteins (ha…
On the occasion of its 20th anniversary, ProBioGen AG announced to invest 20€ million and to double its workforce. CEO D…
On the occasion of its 20th anniversary, ProBioGen AG announced to invest 20€ million and to double its workforce. CEO D…
Anlässlich des 20-jährigen Bestehens der ProBioGen AG begrüßte der Vorstandsvorsitzende Dr. Wieland Wolf am 4. September…
ProBioGen AG announced today that it has signed a non-exclusive commercial multi-product licensing agreement with Novart…
ProBioGen AG and Merus B.V. today announced that the companies have signed a non-exclusive commercial option and license…